Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Learn which Dividend Aristocrats ETF charges the lowest fees and how that can impact long-term performance. We compare expense ratios and help you choose smarter.
27,457 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
If you’re building a retirement roadmap, long-horizon stock bets can compound your wealth. Here are two healthcare-fo...
Apple accelerates its cash-return program with a fresh buyback authorization and a dividend bump, underscoring a disc...
Constellation Energy plunged today after a mix of macro moves and strategic shifts. This guide breaks down the factor...
MicroStrategy announces a sweeping Digital Credit Capital Framework that reshapes how it funds Bitcoin purchases and ...
Cross-border investing in Europe can be tricky because taxes are taken at the source. This guide explains how withhol...
Unum Group operates in the steady world of employer benefits and personal protection. If three key trends line up—und...
As Republic Services reveals Q1 2026 figures, investors gain a window into revenue growth, margins, and cash flow. Th...
BP plc shares slipped as leadership changes hit the headlines and energy markets swung on oil-price moves. This artic...
Treasury yields are climbing, sending ripples through equities. This piece breaks down why rates are rising, who’s af...
Three dirt-cheap stocks under built below $45 each combine durable cash flow with dividend support, offering ballast ...
Transocean (Rig) 2025 earnings could hinge on fleet utilization and day rates. This guide unpackages the drivers, ris...